The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 28)
Research Grant, 2014
The dopamine precursor levodopa is the gold-standard treatment for Parkinson's disease. However, as PD progresses, serotonin neurons increasingly convert levodopa to dopamine as a "false neurotransmitter." This activity underlies the development of troubling levodopa-induced dyskinesia that affects many PD patients. One strategy is to silence the activity of sero...
Synuclein Therapeutic Acceleration Program, 2013
A role for the synaptic protein alpha-synuclein in Parkinson's disease is suggested by human genetic studies, the histopathology in patients with Parkinson's disease and studies using pre-clinical models. Recent work further suggests that compounds that bind to specific regions of alpha-synuclein can prevent its toxic effects in the brain. We will test whether a compound (NPT2...
Researchers: Douglas William Bonhaus, PhD
Research Grant, 2013
Continuous Subcutaneous Administration of Levodopa/Carbidopa (ND0612) for the Treatment of Parkinson's Disease
Improving consistency of plasma levodopa has been a longstanding pharmacological challenge. ND0612 is a proprietary formulation of levodopa and carbidopa continuously administered subcutaneously, providing more continuous dopaminergic stimulation that would consequently reduce or prevent motor complications in Parkinson's disease (PD) patients. ND0612 was safe, to...
Researchers: Sheila Oren, MD
Therapeutic Pipeline Program, 2013
Pre-clinical Evaluation of Neuroprotective Small Molecule Erythropoietin Receptor Agonists in the Treatment of Parkinson's Disease
Erythropoietin (EPO) receptor is present throughout the body and plays a role in both red blood cell production and tissue protection. STATegics has discovered small molecule EPO receptor agonists (EPORA) that are selective for neuroprotection and demonstrate bioavailability in the brain tissue. The compounds offer potential as candidate therapeutics for Parkins...
Researchers: Juha Punnonen, MD, PhD
MJFF Research Grant, 2013
A Study to Evaluate Feasibility, Safety and Preliminary Efficacy of Magnetic Resonance Image Guided Focused Ultrasound for the Treatment of Parkinson's Disease Dyskinesia
The effectiveness of drug therapy to alleviate Parkinson's disease (PD) symptoms often diminishes over time, and side effects such as dyskinesia (involuntary movements) can become prevalent and burdensome. The destruction of a small volume of tissue near the center of the brain (pallidotomy) can often reduce the dyskinesia, yet typical procedures require surgery o...
Researchers: Neal Kassell, MD